Kowa Company Limited

Olympus Corporation

Ryu Oshima

Takashi Saito

Hiroki Moriyama

Masahiro Katakura

Toshiaki Noguchi

Yosuke Yoshimoto

Kensuke Miyake

Yasuyuki Futatsugi

Shoichi Amano

Hitoshi Hasegawa

Yugo Koizumi

Takeshi Urasaki

Mai Ojima

Hiroshi Tamai

Gary Gordon

Masatoshi Ito

Chisato Nagai

Mikihiko Nakagawa

Kota Ishibiki

Kazuhito Suehira

Koji Morishita

Yoshio Tashiro

To provide a medicament for safely treating a patient in need of treatment with pemafibrate, a salt thereof, or a solvate of any of these (hereinafter also referred to as pemafibrate therapy). A medicament for treating a patient in need of pemafibrate therapy, the medicament comprising the step of avoiding or suspending concomitant use of pemafibrate, a salt thereof, or a solvate of any of these as an active ingredient in order to suppress an increase in plasma concentration of pemafibrate when the treatment is combined with a medicament containing an OATP1B inhibitor, or the step of reducing the dose of pemafibrate, a salt thereof, or a solvate of any of these.

Pemafibrate dosing regimens

The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

Methods of treating mixed dyslipidemia and hypertriglycertdemia

An endoscope apparatus including a connector included in an endoscope and connected to an endoscope connection portion of a video processor, a fluid feeding apparatus including a tube configured to transmit fluid to the endoscope, a connection detector configured to detect a connection state of the tube with the connector of the endoscope, a control unit configured to detect an ON/OFF state of a power source of the fluid feeding apparatus, determine an abnormality exists when the connection detector detects that the tube is in a disconnected state with the connector of the endoscope and the power source of the fluid feeding apparatus is detected to be in an ON state, and output a notification of the determined abnormality, and a display configured to display the notification of the abnormality outputted by the control unit.

Endoscope apparatus, activation method, and video processor for determining an abnormality

The present invention relates to pharmacological interventions with pemafibrate for cardiovascular diseases and adverse cardiovascular events. In addition, the invention relates to the use of pemafibrate to treat dyslipidemia and type 2 diabetes mellitus and thereby reduce the risk of cardiovascular disease and adverse cardiovascular events.

Methods of preventing the occurrence of cardiovascular events

The present invention provides pharmacological interventions for the treatment of dyslipidemia, and to the reduction of residual risk of cardiovascular disease and adverse cardiovascular events in patients on intense statin use or with well-controlled LDL-C concentrations. In particular, the invention relates to the use of pemafibrate to prevent cardiovascular events in populations at-risk due to risk factors such as type 2 diabetes mellitus with dyslipidemia in spite of intense statin use or well-controlled LDL-C.

Methods of preventing cardiovascular events in residual risk dyslipidemic populations

Growing community of inventors

Tokyo, Japan

Ryu Oshima